CORESTEMCHEMON Inc. (KOSDAQ: 166480)

Market Cap	123.51B
Revenue (ttm)	28.88B
Net Income (ttm)	-37.94B
Shares Out	24.36M
EPS (ttm)	-1,832.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,546,572
Open	5,200.00
Previous Close	7,240.00
Day's Range	5,070.00 - 5,500.00
52-Week Range	5,070.00 - 15,610.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 20, 2025

About CORESTEMCHEMON

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company was formerly known as Corest...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 355
• Stock Exchange: KOSDAQ
• Ticker Symbol: 166480

Financial Performance

In 2023, CORESTEMCHEMON's revenue was 33.66 billion, a decrease of -26.64% compared to the previous year's 45.88 billion. Losses were -17.67 billion, 682.9% more than in 2022.